BRPI0807569A8 - Péletes compreendendo uma matriz de substância ativa resistentes ao suco gástrico - Google Patents

Péletes compreendendo uma matriz de substância ativa resistentes ao suco gástrico

Info

Publication number
BRPI0807569A8
BRPI0807569A8 BRPI0807569A BRPI0807569A BRPI0807569A8 BR PI0807569 A8 BRPI0807569 A8 BR PI0807569A8 BR PI0807569 A BRPI0807569 A BR PI0807569A BR PI0807569 A BRPI0807569 A BR PI0807569A BR PI0807569 A8 BRPI0807569 A8 BR PI0807569A8
Authority
BR
Brazil
Prior art keywords
pellets
gastric juice
matrix
release
active substances
Prior art date
Application number
BRPI0807569A
Other languages
English (en)
Inventor
Gryczke Andreas
Original Assignee
Evonik Roehm Gmbh
Roehm Gmbh
Evonik Degussa Gmbh
Evonik Operations Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Roehm Gmbh, Roehm Gmbh, Evonik Degussa Gmbh, Evonik Operations Gmbh filed Critical Evonik Roehm Gmbh
Publication of BRPI0807569A2 publication Critical patent/BRPI0807569A2/pt
Publication of BRPI0807569A8 publication Critical patent/BRPI0807569A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

PÉLETES COMPREENDENDO UMA MATRIZ DE SUBSTANCIA ATIVA RESISTENTES AO SUCO GÁSTRICO. A presente invenção refere-se aos péletes tendo um tamanho 5 médio de partícula na faixa de 300 a 1100 um, compreendendo uma substancia farmaceuticamente ativa embutida em uma matriz polimérica de um ou mais polímeros insolúveis em água, caracterizados pelo fato de que a matriz polimérica adicionalmente contém 10 a 90% em peso de um polímero aniônico, e com a condição que os péletes liberem no mais do que 10% do 0 composto ativo contido, no teste de liberação de acordo com a USP, em suco gástrico artificial, em pH 1,2, após 120 min, liberem pelo menos 50% do Composto ative contido apés completamente uns 300 min adicionais, em pH 6.8 e/ou em pH 7,5.
BRPI0807569A 2007-02-22 2008-01-08 Péletes compreendendo uma matriz de substância ativa resistentes ao suco gástrico BRPI0807569A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102007009242.5 2007-02-22
DE102007009242A DE102007009242A1 (de) 2007-02-22 2007-02-22 Pellets mit magensaftresistenter Wirkstoff-Matix
PCT/EP2008/050124 WO2008101743A2 (de) 2007-02-22 2008-01-08 Pellets mit magensaftresistenter wirkstoff-matrix

Publications (2)

Publication Number Publication Date
BRPI0807569A2 BRPI0807569A2 (pt) 2014-07-01
BRPI0807569A8 true BRPI0807569A8 (pt) 2022-07-05

Family

ID=39687953

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0807569A BRPI0807569A8 (pt) 2007-02-22 2008-01-08 Péletes compreendendo uma matriz de substância ativa resistentes ao suco gástrico

Country Status (12)

Country Link
US (1) US8216613B2 (pt)
EP (1) EP2120880A2 (pt)
JP (1) JP2010519236A (pt)
KR (1) KR101500769B1 (pt)
CN (2) CN101610755A (pt)
BR (1) BRPI0807569A8 (pt)
CA (1) CA2679010C (pt)
DE (1) DE102007009242A1 (pt)
HK (1) HK1205684A1 (pt)
IL (1) IL199637B (pt)
MX (1) MX2009008952A (pt)
WO (1) WO2008101743A2 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
DE102007009243A1 (de) * 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets
CA2717947C (en) * 2008-03-11 2020-07-07 Takeda Pharmaceutical Company Limited Orally-disintegrating solid preparation
EP2309999A1 (en) * 2008-06-26 2011-04-20 McNeil-PPC, Inc. Coated particles containing pharmaceutically active agents
CA2734646C (en) * 2008-08-20 2016-06-28 James W. Mcginity Hot-melt extrusion of modified release multi-particulates
CA2745383A1 (en) * 2008-12-01 2010-06-10 In Vasc Therapeutics, Inc. Compositions comprising renin-angiotensin aldosterone system inhibitors and lipoic acid compounds, and the use thereof for the treatment of renin-angiotensin aldosterone system related disorders
US20120058936A1 (en) 2009-03-13 2012-03-08 Assistance Publique - Hopitaux De Paris Compositions and methods for elimination of gram negative bacteria
ES2586135T3 (es) 2010-02-23 2016-10-11 Da Volterra Formulaciones para el suministro oral de adsorbentes en el intestino
MX346203B (es) 2010-09-28 2017-03-09 Depomed Inc Formas de dosificacion retentivas gastricas para liberacion prolongada de acamprosato en el tracto gastrointestinal superior.
US8597683B2 (en) * 2010-11-30 2013-12-03 Watson Pharmaceuticals, Inc. Modified release tranexamic acid formulation
PT3616695T (pt) 2011-09-09 2024-11-18 Merck Sharp & Dohme Ceftolozano/tazobactam para tratar infeções intrapulmonares
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
CA2863265C (en) * 2011-12-02 2020-04-14 Synchroneuron Inc. Acamprosate formulations, methods of using the same, and combininations comprising the same
CN102552921B (zh) * 2012-02-28 2013-08-21 南京正科制药有限公司 一种孟鲁司特钠组合物
EP2641592A1 (en) * 2012-03-23 2013-09-25 Salmon Pharma GmbH Pharmaceutical formulation comprising bendamustine
US8809314B1 (en) 2012-09-07 2014-08-19 Cubist Pharmacueticals, Inc. Cephalosporin compound
US8476425B1 (en) 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
PE20160048A1 (es) 2013-03-15 2016-02-12 Merck Sharp & Dohme Composiciones antibioticas de ceftolozano
US20140274996A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Tazobactam and ceftolozane antibiotic compositions
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
JP2016520653A (ja) 2013-06-05 2016-07-14 シンクロニューロン インコーポレイテッド アカンプロサート製剤、それを用いる方法、およびそれを含む合剤
CN105491886B (zh) * 2013-08-27 2019-01-29 V·沃道里斯 苯达莫司汀医药组合物
WO2015035376A2 (en) 2013-09-09 2015-03-12 Calixa Therapeutics, Inc. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US8906898B1 (en) 2013-09-27 2014-12-09 Calixa Therapeutics, Inc. Solid forms of ceftolozane
PE20180690A1 (es) 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
JP6824197B2 (ja) 2015-06-05 2021-02-03 エボニック オペレーションズ ゲーエムベーハー エタノールの影響に対する耐性を有する医薬品組成物または栄養機能食品組成物
KR20190039137A (ko) 2016-07-14 2019-04-10 아카오젠, 인코포레이티드 박테리아 감염 치료에서 사용하기 위한 세프티부텐과 클라불란산의 조합
CN107811994B (zh) * 2016-09-12 2020-09-25 江苏艾立康药业股份有限公司 一种西里帕格pH依赖-时滞型结肠靶向微丸及其制备方法
WO2018087109A1 (de) 2016-11-08 2018-05-17 Grünenthal GmbH Multipartikuläre arzneiform mit kontrollierter freisetzung von metamizol
US10966943B2 (en) 2018-09-06 2021-04-06 Innopharmascreen Inc. Methods and compositions for treatment of asthma or parkinson's disease
WO2022101269A1 (en) 2020-11-13 2022-05-19 Da Volterra Formulations and dosage regimen for oral delivery of adsorbents in the gut
CN117257769A (zh) * 2023-10-11 2023-12-22 珠海润都制药股份有限公司 一种替米沙坦微丸及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2135073C3 (de) 1971-07-14 1974-07-11 Roehm Gmbh Überzugsmittel für Arzneiformen
DE3438291A1 (de) 1984-10-19 1986-04-24 Röhm GmbH, 6100 Darmstadt Verfahren zur herstellung einer waessrigen ueberzugsmitteldispersion und ihre verwendung zum ueberziehen von arzneimitteln
DE3809764A1 (de) * 1988-03-23 1989-10-05 Knoll Ag Mischung aus alginaten und polyacrylaten und deren verwendung
CA2007055A1 (en) * 1989-01-06 1990-07-06 Garth Boehm Theophylline dosage form
SE9402431D0 (sv) 1994-07-08 1994-07-08 Astra Ab New tablet formulation
DE9414066U1 (de) 1994-08-31 1994-11-03 Röhm GmbH & Co. KG, 64293 Darmstadt Überzugs- und Bindemittel für Arzneiformen sowie damit hergestellte Arzneiform
DE9414065U1 (de) 1994-08-31 1994-11-03 Röhm GmbH & Co. KG, 64293 Darmstadt Thermoplastischer Kunststoff für darmsaftlösliche Arznei-Umhüllungen
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US6673367B1 (en) * 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
FR2795326B1 (fr) * 1999-06-28 2001-08-31 Adir Composition pharmaceutique solide thermoformable a liberation controlee
DE10011447A1 (de) 2000-03-10 2001-09-20 Roehm Gmbh Dispersion mit nichtionischem Emulgator
DE10013029A1 (de) 2000-03-17 2001-09-20 Roehm Gmbh Mehrschichtige Arzneiform für die Colonfreigabe
WO2002035991A2 (en) * 2000-10-30 2002-05-10 The Board Of Regents, The University Of Texas System Spherical particles produced by a hot-melt extrusion/spheronization process
DE10208335A1 (de) 2002-02-27 2003-09-04 Roehm Gmbh Arzneiform und Verfahren zu ihrer Herstellung
DE10208344A1 (de) * 2002-02-27 2003-09-04 Roehm Gmbh Schmelzextrusion von Wirkstoffsalzen
MXPA04010956A (es) * 2003-01-30 2005-01-25 Roehm Gmbh Forma de dosis farmaceutica y metodo para la produccion de la misma.
JP4961213B2 (ja) * 2004-01-21 2012-06-27 ザ・スクール・オブ・ファーマシー マイクロ粒子の製造方法
GB0403098D0 (en) 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
DE102004007713A1 (de) 2004-02-16 2005-09-01 Leistritz Extrusionstechnik Gmbh Vorrichtung zur Herstellung gerundeter Pellets
DE102004011349A1 (de) 2004-03-05 2005-09-22 Basf Ag Wässrige Polymerdispersion auf Basis von Alkyl(meth)-acrylaten
PT1618873E (pt) * 2004-07-14 2007-09-04 Siegfried Generics Int Ag Grânulos para libertação controlada de tamsulosina, que contém alginato.
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same

Also Published As

Publication number Publication date
IL199637A0 (en) 2010-04-15
WO2008101743A3 (de) 2008-10-09
CA2679010C (en) 2014-09-09
CN101610755A (zh) 2009-12-23
CN104490789A (zh) 2015-04-08
CA2679010A1 (en) 2008-08-28
WO2008101743A2 (de) 2008-08-28
BRPI0807569A2 (pt) 2014-07-01
US8216613B2 (en) 2012-07-10
KR20090112717A (ko) 2009-10-28
JP2010519236A (ja) 2010-06-03
KR101500769B1 (ko) 2015-03-17
DE102007009242A1 (de) 2008-09-18
HK1205684A1 (en) 2015-12-24
MX2009008952A (es) 2009-08-31
US20080206350A1 (en) 2008-08-28
EP2120880A2 (de) 2009-11-25
IL199637B (en) 2018-01-31

Similar Documents

Publication Publication Date Title
MX2009008952A (es) Microesferas que comprenden una matriz de sustancia activa resistente a jugo gastrico.
BRPI0823096B8 (pt) composição farmacêutica de opióide de liberação controlada, dependente do ph, com resistência contra a influência do etanol, processo para sua preparação, e seu uso
ES2525530T3 (es) Sistemas de administración oral de liberación controlada
BR112012008626A2 (pt) forma farmacêutica oral sólida com liberação modificada de pelo menos um ingrediente ativo
BRPI0515390A (pt) composição farmacêutica, compreendendo uma dispersão sólida com matriz polìmero, compreendendo uma fase contìnua de polidextrose e uma fase contìnua de um polìmero além da polidextrose
BRPI0823128B8 (pt) composição farmacêutica de liberação controlada dependente do ph para não opioides com resistência contra a influência de etanol, e processo para sua preparação
BRPI0722042B8 (pt) composição farmacêutica de liberação controlada dependente do ph, e seu processo de preparação
BRPI0513846A (pt) formulação de comprimido de liberação prolongada contendo pramipexol ou um sal farmaceuticamente aceitável do mesmo, método para a fabricação do mesmo e o uso do mesmo
BRPI0924543B8 (pt) composição farmacêutica de liberação controlada, e seu processo de preparação
BR0301694A (pt) Mistura de cimento de ossos e agente de contraste de raios x bem como processo para a sua preparação
BRPI0920242B8 (pt) processo para a preparação de polímero superabsorvente contendo argila
BR0312887A (pt) Forma de dosagem farmacêutica de múltiplos componentes
BRPI0612674B8 (pt) preparação farmacêutica, uso de um antagonista do receptor de angiotensina ii e um bloqueador do canal de cálcio
BR112014013522A2 (pt) material compósito tribológico, de estrutura fina, pigmentado
BRPI0619572B8 (pt) método para a preparação de um carbonato de cálcio revestido com película, método para a preparação de tablete farmacêutico ou nutricional compreendendo um carbonato de cálcio revestido com película, carbonato de cálcio revestido com película e composição farmacêutica ou nutricional
WO2008071407A3 (de) Beschichtete pellets
ATE382337T1 (de) Bioabsorbierbare pharmazeutische zusammensetzung enthaltend einen plga-copolymer
BRPI0815424A2 (pt) particulando polimérico revestido e processo para revestir um particulado polimérico
WO2008149320A3 (en) Slow release pharmaceutical composition made of microparticles
MX339671B (es) Forma oral solida con perfil de liberacion dual que contiene particulas multiples.
Mahmood et al. An in-vitro exploration of permeation enhancement by novel polysulfonate thiomers
BR0315563A (pt) Dispersões poliméricas estáveis e processos para sua preparação
BRPI0512452A (pt) processo de encapsulamento e microcápsula
Cagnetta et al. Reusable antimicrobial antibiotic-free dressings obtained by photopolymerization
Bulut et al. Development and characterization of pH-sensitive locust bean gum-alginate microspheres for controlled release of ibuprofen

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25D Requested change of name of applicant approved

Owner name: ROEHM GMBH (DE)

B25G Requested change of headquarter approved

Owner name: ROEHM GMBH (DE)

B25A Requested transfer of rights approved

Owner name: EVONIK DEGUSSA GMBH (DE)

B25D Requested change of name of applicant approved

Owner name: EVONIK OPERATIONS GMBH (DE)